Developer docs
API playgroundTry for free, no card

Search company profiles

CEL-SCI

Full company profile

uuid0000yx9

Namestring
CEL-SCI
Legal namestring
CEL-SCI Corporation
Websiteurl
cel-sci.com
Company typeenum
Public
Founded yearint
1983
Descriptiontext

CEL-SCI Corporation (NYSE American: CVM) is a Vienna, Virginia-based clinical-stage biotechnology company founded in 1983 that develops immunotherapy products for cancer, autoimmune, and infectious diseases. The company's lead asset is Multikine (Leukocyte Interleukin, Injection), a patented defined mixture of 14 naturally occurring pro-inflammatory human cytokines (interleukins, interferons, chemokines, and colony-stimulating factors) administered as neoadjuvant therapy before standard-of-care surgery, radiation, or chemotherapy in newly diagnosed advanced primary head and neck cancer. Multikine received FDA Orphan Drug designation and was studied in a 928-patient global Phase III trial — the largest ever in head and neck cancer — across approximately 100 centers in North America, Europe, and Asia, which reported statistically significant 5-year overall survival benefit (62.7% vs 48.6% control; 14.1% absolute advantage) in the surgery-plus-radiotherapy arm. A secondary platform, LEAPS (Ligand Epitope Antigen Presentation System), is a patented T-cell modulation peptide technology with development candidates for rheumatoid arthritis (CEL-2000, CEL-4000) and pandemic influenza.

CEL-SCI operates a 73,000 square foot purpose-built cGMP manufacturing facility outside Baltimore, Maryland with True Cold Fill capability, intended to support commercial supply of Multikine pending FDA approval. The company is pre-revenue with no commercialized products and has historically funded operations through repeated small-cap public equity offerings (over $75 million raised since 2021, primarily via ThinkEquity as placement agent), supplemented by a Phase II SBIR grant from NIH for LEAPS development. Q1 FY2026 (ending December 31, 2025) net loss was $5.5 million, improved from $7.1 million in the prior-year period, with R&D expenses of $3.7 million. The company's regulatory strategy includes preparing a BLA/NDA submission for Multikine to the FDA following a planned 212-patient confirmatory Registration Study targeted to commence enrollment in summer 2026, plus a Breakthrough Medicine Designation application to the Saudi FDA via a June 2026 strategic agreement with Saudi AmaroX.

The company is led by long-tenured CEO Geert R. Kersten (since 1987/CEO since 1995), CSO Dr. Eyal Talor (since 1993, inventor on ten issued patents), Acting CMO Dr. Giovanni Selvaggi (since May 2024), and CFO/COO Patricia B. Prichep (with the company since 1992, promoted November 2024). Customer concentration is not yet a relevant risk because CEL-SCI has no paying customers; however, the Phase III trial database and physician relationships at ~100 oncology centers represent the foundational commercial channel for potential launch. The company holds an FDA Orphan Drug designation granting 7-year marketing exclusivity upon approval and has secured regulatory clearance from 24 agencies globally for its Phase III program.

Short descriptiontext

CEL-SCI Corporation is a Vienna, VA-based clinical-stage biotechnology company developing Multikine, an investigational neoadjuvant immunotherapy for newly diagnosed advanced head and neck cancer, along with the LEAPS T-cell modulation peptide platform for autoimmune and infectious diseases. The company is pre-revenue and preparing for FDA BLA submission following a planned confirmatory Phase III study.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVienna, United States
HQ citystring
Vienna
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, head and neck cancer, cytokine therapy, neoadjuvant immunotherapy, biologic drug development
Industry3 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue (Future)
TypeOne Time License
Description

CEL-SCI is a pre-revenue clinical-stage biotechnology company. The company has not commercialized any products. If Multikine receives FDA approval, the company plans to commercialize the drug directly or through partnerships. Revenue would come from pharmaceutical product sales for head and neck cancer treatment.

cel-sci.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Multikine
Description

Leukocyte Interleukin, Injection - CEL-SCI's lead investigational immunotherapy for head and neck cancer

cel-sci.com
+1 more record
Core offering1 text field

CEL-SCI is developing Multikine (Leukocyte Interleukin, Injection), an investigational combination immunotherapy consisting of a defined mixture of 14 pro-inflammatory human cytokines, intended as neoadjuvant therapy administered prior to surgery, radiation, and chemotherapy for newly diagnosed advanced primary head and neck cancer. The company also operates the LEAPS (Ligand Epitope Antigen Presentation System) platform, a patented T-cell modulation technology for designing peptide immunogens targeting rheumatoid arthritis (CEL-2000, CEL-4000) and infectious diseases including influenza.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 14.1% absolute 5-year survival advantage for Multikine-treated patients vs control (62.7% vs 48.6%) in surgery + radiotherapy arm; p-value 0.0236 exceeding protocol requirement of <0.05; Hazard Ratio 0.68 exceeding protocol requirement of 0.721
+3 more records
Product overview1 text field

CEL-SCI is a late-stage cancer immunotherapy company with two main technology platforms. The core product is Multikine (Leukocyte Interleukin, Injection), an investigational combination immunotherapy consisting of 14 pro-inflammatory cytokines being developed for neoadjuvant treatment of advanced primary head and neck cancer. Multikine is administered prior to surgery, radiation, and chemotherapy to boost the immune system while it is still intact. The second platform is LEAPS (Ligand Epitope Antigen Presentation System), a T-cell modulation technology that enables design of peptide immunogens for autoimmune diseases (rheumatoid arthritis candidates CEL-2000, CEL-4000) and infectious diseases (influenza).

Product and service5 records
1Multikine (Leukocyte Interleukin, Injection)
CategoryCancer Immunotherapy
Description

Investigational combination immunotherapy defined mixture of 14 pro-inflammatory human cytokines administered as neoadjuvant therapy prior to surgery, radiation, and chemotherapy for newly diagnosed advanced primary head and neck cancer. Phase III demonstrated 14.1% absolute 5-year overall survival benefit (62.7% vs 48.6% control) in surgery plus radiotherapy arm with no added safety toxicity.

2LEAPS (Ligand Epitope Antigen Presentation System) Platform
CategoryImmunotherapy Platform Technology
Description

Patented T-cell modulation peptide epitope delivery platform technology that enables design and synthesis of proprietary peptide immunogens combining T-cell binding ligands with disease-associated peptide antigens. Supports drug candidates for autoimmune diseases and infectious diseases.

3CEL-4000 (LEAPS Rheumatoid Arthritis Vaccine Candidate)
CategoryAutoimmune Disease Therapeutic
Description

LEAPS-based drug candidate for rheumatoid arthritis where Th1 signature cytokine (IFN-γ) is dominant. Being developed as a therapeutic vaccine with potential for disease-specific therapy that acts earlier in the disease process than current treatments.

4CEL-2000 (LEAPS Rheumatoid Arthritis Vaccine Candidate)
CategoryAutoimmune Disease Therapeutic
Description

LEAPS-based drug candidate for rheumatoid arthritis with Th17 signature cytokine TNF-α. Being developed as a therapeutic vaccine demonstrating effectiveness with fewer administrations than current anti-rheumatoid arthritis treatments.

5LEAPS H1N1 / J-LEAPS Influenza Treatment
CategoryInfectious Disease Therapeutic
Description

Peptide treatment candidate for H1N1 (swine flu) and pandemic influenza. Designed to focus on conserved, non-changing epitopes of Type A Influenza viruses including H1N1, H5N1, and H3N1 strains to minimize viral escape from immune recognition.

Scale indicator18 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Saudi AmaroX
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Strategic agreement signing ceremony held at Bio 2026 to advance U.S.-Saudi cooperation in cancer care. The partnership focuses on bringing Multikine therapy to Saudi Arabia and the Middle East market. CEL-SCI has submitted a Breakthrough Medicine Designation application to Saudi Food and Drug Authority (SFDA) for Multikine in head and neck cancer.

ainvest.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative research with Dr. Tibor Glant and Dr. Katalin Mikecz laboratories for LEAPS technology development in rheumatoid arthritis. Work conducted on CEL-4000 and CEL-2000 RA vaccine candidates.

3NIAID (National Institute of Allergy and Infectious Diseases)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborated with NIAID scientists led by Dr. Kanta Subbarao on LEAPS H1N1 flu treatment research. NIAID scientists presented positive efficacy data in mice at Keystone Conference 2011.

cel-sci.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage oncology company developing antibody-based immunotherapies including bispecifics. Comparable therapeutic modality (biologic immunotherapy) and similar clinical-stage status.

2Bristol-Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical company with Opdivo (nivolumab) approved for head and neck cancer. Sets the competitive benchmark for immunotherapy in CEL-SCI's lead indication and represents a potential acquirer.

TypeEmerging player
Description

Clinical-stage cancer immunotherapy company using computational discovery to identify novel immune targets. Comparable as a small-cap IO developer with multiple pipeline assets.

TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered TCR-T therapies for solid tumors. Comparable as a small-cap oncology immunotherapy developer targeting solid tumor indications.

TypeBroad incumbent
Description

Large biotech with Libtayo (cemiplimab) approved in head and neck cancer and a broader oncology immunotherapy pipeline. Representative of large-cap strategic acquirers and direct competitive benchmark.

TypeBroad incumbent
Description

Large pharmaceutical company with Keytruda (pembrolizumab) approved for head and neck cancer. Dominant incumbent in the indication CEL-SCI targets and benchmark for IO pricing/penetration.

TypeEmerging player
Description

Clinical-stage developer of IL-2-based immunotherapy for head and neck cancer and other indications. Highly comparable therapeutic area overlap with Multikine's lead indication.

8Innate Pharma
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing antibody-based therapies that modulate the innate immune system for cancer treatment. Comparable to CEL-SCI as a small/mid-cap focused cancer immunotherapy developer.

TypeDirect peer
Description

Clinical-stage cell therapy company focused on tumor-infiltrating lymphocyte (TIL) therapy for solid tumors including head and neck cancer. Direct peer in late-stage cancer immunotherapy development with similar scale and pre-revenue profile.

TypeDirect peer
Description

Clinical-stage developer of cytokine-based immunotherapies (e.g., bempegaldesleukin). Closely comparable to CEL-SCI in leveraging cytokine mechanisms to drive anti-tumor immune responses, with similar small-cap clinical-stage profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds19 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CEL-SCI

Cancer Immunotherapy Pharmaceuticalscel-sci.com

CEL-SCI Corporation is a Vienna, VA-based clinical-stage biotechnology company developing Multikine, an investigational neoadjuvant immunotherapy for newly diagnosed advanced head and neck cancer, along with the LEAPS T-cell modulation peptide platform for autoimmune and infectious diseases. The company is pre-revenue and preparing for FDA BLA submission following a planned confirmatory Phase III study.

What CEL-SCI does

CEL-SCI Corporation (NYSE American: CVM) is a Vienna, Virginia-based clinical-stage biotechnology company founded in 1983 that develops immunotherapy products for cancer, autoimmune, and infectious diseases. The company's lead asset is Multikine (Leukocyte Interleukin, Injection), a patented defined mixture of 14 naturally occurring pro-inflammatory human cytokines (interleukins, interferons, chemokines, and colony-stimulating factors) administered as neoadjuvant therapy before standard-of-care surgery, radiation, or chemotherapy in newly diagnosed advanced primary head and neck cancer. Multikine received FDA Orphan Drug designation and was studied in a 928-patient global Phase III trial — the largest ever in head and neck cancer — across approximately 100 centers in North America, Europe, and Asia, which reported statistically significant 5-year overall survival benefit (62.7% vs 48.6% control; 14.1% absolute advantage) in the surgery-plus-radiotherapy arm. A secondary platform, LEAPS (Ligand Epitope Antigen Presentation System), is a patented T-cell modulation peptide technology with development candidates for rheumatoid arthritis (CEL-2000, CEL-4000) and pandemic influenza.

CEL-SCI operates a 73,000 square foot purpose-built cGMP manufacturing facility outside Baltimore, Maryland with True Cold Fill capability, intended to support commercial supply of Multikine pending FDA approval. The company is pre-revenue with no commercialized products and has historically funded operations through repeated small-cap public equity offerings (over $75 million raised since 2021, primarily via ThinkEquity as placement agent), supplemented by a Phase II SBIR grant from NIH for LEAPS development. Q1 FY2026 (ending December 31, 2025) net loss was $5.5 million, improved from $7.1 million in the prior-year period, with R&D expenses of $3.7 million. The company's regulatory strategy includes preparing a BLA/NDA submission for Multikine to the FDA following a planned 212-patient confirmatory Registration Study targeted to commence enrollment in summer 2026, plus a Breakthrough Medicine Designation application to the Saudi FDA via a June 2026 strategic agreement with Saudi AmaroX.

The company is led by long-tenured CEO Geert R. Kersten (since 1987/CEO since 1995), CSO Dr. Eyal Talor (since 1993, inventor on ten issued patents), Acting CMO Dr. Giovanni Selvaggi (since May 2024), and CFO/COO Patricia B. Prichep (with the company since 1992, promoted November 2024). Customer concentration is not yet a relevant risk because CEL-SCI has no paying customers; however, the Phase III trial database and physician relationships at ~100 oncology centers represent the foundational commercial channel for potential launch. The company holds an FDA Orphan Drug designation granting 7-year marketing exclusivity upon approval and has secured regulatory clearance from 24 agencies globally for its Phase III program.

CEL-SCI firmographics

Firmographics
Name
CEL-SCI
Legal name
CEL-SCI Corporation
Website
https://cel-sci.com
Company type
Public
Founded year
1983
Operating status
Operating
Headcount range
11–50 employees
Short description
CEL-SCI Corporation is a Vienna, VA-based clinical-stage biotechnology company developing Multikine, an investigational neoadjuvant immunotherapy for newly diagnosed advanced head and neck cancer, along with the LEAPS T-cell modulation peptide platform for autoimmune and infectious diseases. The company is pre-revenue and preparing for FDA BLA submission following a planned confirmatory Phase III study.
Ownership category
akta.pro rank

CEL-SCI industry classification

Industry
Product category
Cancer Immunotherapy Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Keywords

  • Cancer immunotherapy
  • Head and neck cancer
  • Cytokine therapy
  • Neoadjuvant immunotherapy
  • Biologic drug development

Where CEL-SCI is headquartered

Location

Headquarters

HQ city
Vienna
HQ country
United States
HQ region
North America

Offices5 records

Markets served

CEL-SCI business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Revenue (Future): CEL-SCI is a pre-revenue clinical-stage biotechnology company. The company has not commercialized any products. If Multikine receives FDA approval, the company plans to commercialize the drug directly or through partnerships. Revenue would come from pharmaceutical product sales for head and neck cancer treatment.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

CEL-SCI product offering

Product offering

Core offering

CEL-SCI is developing Multikine (Leukocyte Interleukin, Injection), an investigational combination immunotherapy consisting of a defined mixture of 14 pro-inflammatory human cytokines, intended as neoadjuvant therapy administered prior to surgery, radiation, and chemotherapy for newly diagnosed advanced primary head and neck cancer. The company also operates the LEAPS (Ligand Epitope Antigen Presentation System) platform, a patented T-cell modulation technology for designing peptide immunogens targeting rheumatoid arthritis (CEL-2000, CEL-4000) and infectious diseases including influenza.

Product overview

CEL-SCI is a late-stage cancer immunotherapy company with two main technology platforms. The core product is Multikine (Leukocyte Interleukin, Injection), an investigational combination immunotherapy consisting of 14 pro-inflammatory cytokines being developed for neoadjuvant treatment of advanced primary head and neck cancer. Multikine is administered prior to surgery, radiation, and chemotherapy to boost the immune system while it is still intact. The second platform is LEAPS (Ligand Epitope Antigen Presentation System), a T-cell modulation technology that enables design of peptide immunogens for autoimmune diseases (rheumatoid arthritis candidates CEL-2000, CEL-4000) and infectious diseases (influenza).

Differentiator

Problem solved

Functional benefit

Brands

  • Multikine: Leukocyte Interleukin, Injection - CEL-SCI's lead investigational immunotherapy for head and neck cancer
  • LEAPS

Products and services

  • Multikine (Leukocyte Interleukin, Injection) Investigational combination immunotherapy defined mixture of 14 pro-inflammatory human cytokines administered as neoadjuvant therapy prior to surgery, radiation, and chemotherapy for newly diagnosed advanced primary head and neck cancer. Phase III demonstrated 14.1% absolute 5-year overall survival benefit (62.7% vs 48.6% control) in surgery plus radiotherapy arm with no added safety toxicity.
  • LEAPS (Ligand Epitope Antigen Presentation System) Platform Patented T-cell modulation peptide epitope delivery platform technology that enables design and synthesis of proprietary peptide immunogens combining T-cell binding ligands with disease-associated peptide antigens. Supports drug candidates for autoimmune diseases and infectious diseases.
  • CEL-4000 (LEAPS Rheumatoid Arthritis Vaccine Candidate) LEAPS-based drug candidate for rheumatoid arthritis where Th1 signature cytokine (IFN-γ) is dominant. Being developed as a therapeutic vaccine with potential for disease-specific therapy that acts earlier in the disease process than current treatments.
  • CEL-2000 (LEAPS Rheumatoid Arthritis Vaccine Candidate) LEAPS-based drug candidate for rheumatoid arthritis with Th17 signature cytokine TNF-α. Being developed as a therapeutic vaccine demonstrating effectiveness with fewer administrations than current anti-rheumatoid arthritis treatments.
  • LEAPS H1N1 / J-LEAPS Influenza Treatment Peptide treatment candidate for H1N1 (swine flu) and pandemic influenza. Designed to focus on conserved, non-changing epitopes of Type A Influenza viruses including H1N1, H5N1, and H3N1 strains to minimize viral escape from immune recognition.

Quantifiable outcome

  • 14.1% absolute 5-year survival advantage for Multikine-treated patients vs control (62.7% vs 48.6%) in surgery + radiotherapy arm; p-value 0.0236 exceeding protocol requirement of <0.05; Hazard Ratio 0.68 exceeding protocol requirement of 0.721
  • +3 more outcomes

Companies that use CEL-SCI

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

CEL-SCI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CEL-SCI partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Saudi AmaroXcoreStrategic or Co-development Partner · 24 June 2026Strategic agreement signing ceremony held at Bio 2026 to advance U.S.-Saudi cooperation in cancer care. The partnership focuses on bringing Multikine therapy to Saudi Arabia and the Middle East market. CEL-SCI has submitted a Breakthrough Medicine Designation application to Saudi Food and Drug Authority (SFDA) for Multikine in head and neck cancer.
  • Rush University Medical CenterminorStrategic or Co-development PartnerCollaborative research with Dr. Tibor Glant and Dr. Katalin Mikecz laboratories for LEAPS technology development in rheumatoid arthritis. Work conducted on CEL-4000 and CEL-2000 RA vaccine candidates.
  • NIAID (National Institute of Allergy and Infectious Diseases)minorStrategic or Co-development PartnerCollaborated with NIAID scientists led by Dr. Kanta Subbarao on LEAPS H1N1 flu treatment research. NIAID scientists presented positive efficacy data in mice at Keystone Conference 2011.

Scale indicators18 records

Recent moves7 records

Expansion highlights5 records

CEL-SCI competitors and assessment

Company assessment

Emerging players

  • MacroGenics: Clinical-stage oncology company developing antibody-based immunotherapies including bispecifics. Comparable therapeutic modality (biologic immunotherapy) and similar clinical-stage status.
  • Compugen: Clinical-stage cancer immunotherapy company using computational discovery to identify novel immune targets. Comparable as a small-cap IO developer with multiple pipeline assets.
  • Cue Biopharma: Clinical-stage developer of IL-2-based immunotherapy for head and neck cancer and other indications. Highly comparable therapeutic area overlap with Multikine's lead indication.

Broad incumbents

  • Bristol-Myers Squibb: Large pharmaceutical company with Opdivo (nivolumab) approved for head and neck cancer. Sets the competitive benchmark for immunotherapy in CEL-SCI's lead indication and represents a potential acquirer.
  • Regeneron Pharmaceuticals: Large biotech with Libtayo (cemiplimab) approved in head and neck cancer and a broader oncology immunotherapy pipeline. Representative of large-cap strategic acquirers and direct competitive benchmark.
  • Merck & Co. Large pharmaceutical company with Keytruda (pembrolizumab) approved for head and neck cancer. Dominant incumbent in the indication CEL-SCI targets and benchmark for IO pricing/penetration.

Direct peers

  • Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR-T therapies for solid tumors. Comparable as a small-cap oncology immunotherapy developer targeting solid tumor indications.
  • Innate Pharma: Clinical-stage immuno-oncology company developing antibody-based therapies that modulate the innate immune system for cancer treatment. Comparable to CEL-SCI as a small/mid-cap focused cancer immunotherapy developer.
  • Iovance Biotherapeutics: Clinical-stage cell therapy company focused on tumor-infiltrating lymphocyte (TIL) therapy for solid tumors including head and neck cancer. Direct peer in late-stage cancer immunotherapy development with similar scale and pre-revenue profile.
  • Nektar Therapeutics: Clinical-stage developer of cytokine-based immunotherapies (e.g., bempegaldesleukin). Closely comparable to CEL-SCI in leveraging cytokine mechanisms to drive anti-tumor immune responses, with similar small-cap clinical-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

CEL-SCI social profiles

Digital presence

CEL-SCI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CEL-SCI leadership team

Management profile

Number of profiles

Profiles9 records

CEL-SCI funding detail

Funding detail

Funding overview

Funding rounds19 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CEL-SCI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CEL-SCI

What does CEL-SCI do?

CEL-SCI is developing Multikine (Leukocyte Interleukin, Injection), an investigational combination immunotherapy consisting of a defined mixture of 14 pro-inflammatory human cytokines, intended as neoadjuvant therapy administered prior to surgery, radiation, and chemotherapy for newly diagnosed advanced primary head and neck cancer. The company also operates the LEAPS (Ligand Epitope Antigen Presentation System) platform, a patented T-cell modulation technology for designing peptide immunogens targeting rheumatoid arthritis (CEL-2000, CEL-4000) and infectious diseases including influenza.

Is CEL-SCI a public or private company?

CEL-SCI is a public company. It is classified as public and is currently operating.

When was CEL-SCI founded?

CEL-SCI was founded in 1983. It employs 11 to 50 people.

Where is CEL-SCI based?

CEL-SCI is headquartered in Vienna, United States, in the North America region.

How does CEL-SCI make money?

One revenue line is on record: pharmaceutical Product Revenue (Future).

Who are CEL-SCI's main competitors?

Emerging players on record are MacroGenics, Compugen and Cue Biopharma. Broad incumbents are Bristol-Myers Squibb, Regeneron Pharmaceuticals and Merck & Co.. Direct peers are Adaptimmune Therapeutics, Innate Pharma, Iovance Biotherapeutics and Nektar Therapeutics.

Does CEL-SCI have an API?

No public API is recorded for CEL-SCI.

What industry is CEL-SCI in?

CEL-SCI's product category is Cancer Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BloombergOncoclinicas Holder Must Make Tender Offer, Brazil Agency Says - BloombergBrazil's securities regulator CVM ruled that US asset manager Centaurus Capital LP must make a tender offer for shares of Oncoclinicas do Brasil Servicos Medicos SA, overturning the regulator's technical staff recommendation. The board voted 3-0 on Tuesday, citing a 2024 restructuring involving investment vehicles linked to Goldman Sachs and Centaurus.YahooCEL-SCI Reports Fiscal Third Quarter 2026 ResultsCEL-SCI Corporation reported fiscal third-quarter 2026 financial results, including a net loss of $5.7 million and approximately $9.7 million in gross proceeds, while announcing key clinical and commercial developments for its investigational therapy Multikine. The company published peer-reviewed data identifying biomarkers to select patients likely to benefit from the treatment and signed a strategic partnership with Amarox to advance regulatory approval and commercialization in Saudi Arabia.BioSpaceCEL-SCI Reports Fiscal Third Quarter 2026 ResultsCEL-SCI reported Q3 2026 results with a $5.7 million net loss and $9.7 million in gross proceeds. The company will start enrollment in its 212-patient Confirmatory Registration Study and partnered with Amarox for Saudi Arabia approval, aiming for near-term commercial availability.BioSpaceCEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine’s Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration StudyCEL-SCI published a study in Oral Oncology showing Multikine neoadjuvant treatment improved overall survival in oral cancer patients with low or zero PD-L1 expression and no lymph node involvement. The study reported a 73.4% five-year survival rate versus 45.8% for control, and a 49% reduction in progression-free survival risk. The company plans to start enrollment in its confirmatory registration study.MorningstarCEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration StudyCEL-SCI published a study in Oral Oncology showing Multikine neoadjuvant treatment improved five-year overall survival to 73.4% versus 45.8% in biomarker-selected oral cancer patients. The study also reported a 49% reduction in disease progression risk. The company plans to start enrollment in a confirmatory registration study.BioSpaceLeading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer PatientsCEL-SCI's Phase 3 data showing Multikine's overall survival benefit in low PD-L1 oral cancer patients was accepted for publication in Oral Oncology. The study reported a 73% five-year survival rate versus 45% with standard care. The company is preparing to enroll patients in its Confirmatory Registration Study VIENNA.BioSpaceCEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerCEL-SCI announced a global confirmatory registration study for Multikine as neoadjuvant therapy for newly diagnosed head and neck cancer, enrolling about 212 patients. The study is powered at 97% to confirm a 0.34 hazard ratio, and pre-surgical responses may support accelerated approval.AInvestCel-Sci and Saudi AmaroX hold strategic agreement signing ceremony at Bio 2026, advancing U.S.–Saudi cooperation in cancer careCel-Sci and Saudi AmaroX held a strategic agreement signing ceremony at Bio 2026 to advance cancer care cooperation between the United States and Saudi Arabia. The article provides limited details beyond confirming the signing ceremony and its focus on U.S.-Saudi collaboration in cancer treatment. No financial terms, specific agreements, or implementation timelines were disclosed in the available content.BioSpaceCEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer CareCEL-SCI and Saudi Amarox signed a strategic agreement at BIO 2026 to commercialize Multikine for head and neck cancer in Saudi Arabia, with potential expansion to GCC countries. The agreement covers regulatory, marketing, distribution, and revenue sharing, building on CEL-SCI's Phase 3 trial showing 73% five-year survival versus 45% with standard care.BioSpaceCEL-SCI Announces Closing of Offering - June 16, 2026CEL-SCI closed a best-efforts offering of 2.5 million shares at $1 each, generating approximately $2.5 million in gross proceeds. The company will use net proceeds for Multikine development, corporate purposes, and working capital. The offering was made under a shelf registration statement filed with the SEC.